The practical effect is that biosimilar developers operate with substantially less pre-investment visibility into patent risk than their generic drug counterparts a key reason why the biosimilar market has matured more slowly than the generic drug market despite being launched with similar policy intent
Reading the dates as a sequence: a clerical issue (a withdrawn nomination), a three-week regulatory gap (April 22 to May 5), a clarification, an updated reference document (May 14), and a future PCAC review that will run alongside the broader peptide policy fight already on the agency's calendar
Over time, preclinical research expanded into tendon, ligament, muscle, and bone healing, which is why it became popular in recovery-focused peptide therapy
These products are hype, not healthcare
Every medication comes with a list of possible serious side effects, even common medicines like paracetamol